{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T19:57:37Z","timestamp":1760385457396,"version":"3.37.3"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Sunovion Pharmaceuticals Inc., Fort Lee, NJ","award":["PROTOCOL NO. DI050303"],"award-info":[{"award-number":["PROTOCOL NO. DI050303"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12888-015-0629-0","type":"journal-article","created":{"date-parts":[[2015,10,31]],"date-time":"2015-10-31T02:58:35Z","timestamp":1446260315000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Treatment of early non-response in patients with schizophrenia: assessing the efficacy of antipsychotic dose escalation"],"prefix":"10.1186","volume":"15","author":[{"given":"Antony","family":"Loebel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6098-9266","authenticated-orcid":false,"given":"Leslie","family":"Citrome","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph U.","family":"Correll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josephine","family":"Cucchiaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John M.","family":"Kane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,10,31]]},"reference":[{"key":"629_CR1","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.schres.2008.02.021","volume":"102","author":"BJ Kinon","year":"2008","unstructured":"Kinon BJ, Chen L, Ascher-Svanum H, Stauffer VL, Kollack-Walker S, Sniadecki JL, et al. Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophr Res. 2008;102:230\u201340.","journal-title":"Schizophr Res"},{"key":"629_CR2","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1001\/archpsyc.60.12.1228","volume":"60","author":"O Agid","year":"2003","unstructured":"Agid O, Kapur S, Arenovich T, Zipursky RB. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry. 2003;60:1228\u201335.","journal-title":"Arch Gen Psychiatry"},{"key":"629_CR3","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/j.biopsych.2005.02.023","volume":"57","author":"S Leucht","year":"2005","unstructured":"Leucht S, Busch R, Hamann J, Kissling W, Kane JM. Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biol Psychiatry. 2005;57:1543\u20139.","journal-title":"Biol Psychiatry"},{"key":"629_CR4","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1176\/appi.ajp.160.11.2063","volume":"160","author":"CU Correll","year":"2013","unstructured":"Correll CU, Malhotra AK, Kaushik S, McMeniman M, Kane JM. Early prediction of antipsychotic response in schizophrenia. Am J Psychiatry. 2013;160:2063\u20135.","journal-title":"Am J Psychiatry"},{"key":"629_CR5","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/npp.2009.164","volume":"35","author":"BJ Kinon","year":"2010","unstructured":"Kinon BJ, Chen L, Ascher-Svanum H, Stauffer VL, Kollack-Walker S, Zhou W, et al. Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. Neuropsychopharmacology. 2010;35:581\u201390.","journal-title":"Neuropsychopharmacology"},{"key":"629_CR6","doi-asserted-by":"crossref","unstructured":"Correll CU, Pikalov A, Hsu J, Cucchiaro J, Goldman R, Loebel A. Early improvement predicts endpoint response to lurasidone in schizophrenia: pooled analysis of five double-blind trials. Poster presentation. American Psychiatric Association, May 3\u20137, 2014, New York, NY","DOI":"10.1016\/S0924-977X(13)70768-5"},{"key":"629_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.9758\/cpn.2014.12.1.1","volume":"12","author":"K Hatta","year":"2014","unstructured":"Hatta K, Ito H. Strategies for Early Non-response to Antipsychotic Drugs in the Treatment of Acute-phase Schizophrenia. Clin Psychopharmacol Neurosci. 2014;12:1\u20137.","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"629_CR8","first-page":"309","volume":"29","author":"BJ Kinon","year":"1993","unstructured":"Kinon BJ, Kane JM, Johns C, Perovich R, Ismi M, Koreen A, et al. Treatment of neuroleptic-resistant schizophrenic relapse. Psychopharmacol Bull. 1993;29:309\u201314.","journal-title":"Psychopharmacol Bull"},{"key":"629_CR9","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/JCP.0b013e31820f4fe0","volume":"31","author":"JP Lindenmayer","year":"2011","unstructured":"Lindenmayer JP, Citrome L, Khan A, Kaushik S, Kaushik S. A randomized, double-blind, parallel-group, fixed-dose, clinical trial of quetiapine at 600 versus 1200 mg\/d for patients with treatment-resistant schizophrenia or schizoaffective disorder. J Clin Psychopharmacol. 2011;31:160\u20138.","journal-title":"J Clin Psychopharmacol"},{"key":"629_CR10","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4088\/JCP.10m06194","volume":"73","author":"WG Honer","year":"2012","unstructured":"Honer WG, MacEwan GW, Gendron A, Stip E, Labelle A, Williams R, et al. A randomized, double-blind, placebo-controlled study of the safety and tolerability of high-dose quetiapine in patients with persistent symptoms of schizophrenia or schizoaffective disorder. J Clin Psychiatry. 2012;73:13\u201320.","journal-title":"J Clin Psychiatry"},{"key":"629_CR11","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/JCP.0b013e3182977308","volume":"33","author":"DC Goff","year":"2013","unstructured":"Goff DC, McEvoy JP, Citrome L, Mech AW, Bustillo JR, Gil R, et al. High-dose oral ziprasidone versus conventional dosing in schizophrenia patients with residual symptoms: the ZEBRAS study. J Clin Psychopharmacol. 2013;33:485\u201390.","journal-title":"J Clin Psychopharmacol"},{"key":"629_CR12","unstructured":"Latuda: US Package Insert. 2013. [ http:\/\/www.latuda.com\/LatudaPrescribingInformation.pdf ]. Accessed October 12, 2015."},{"key":"629_CR13","unstructured":"Latuda: EU Summary of Product Characteristics. 2014. [ http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002713\/WC500164683.pdf ]. Accessed October 12, 2015."},{"key":"629_CR14","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.schres.2013.01.009","volume":"145","author":"A Loebel","year":"2013","unstructured":"Loebel A, Cucchiaro J, Sarma K, Xu L, Hsu C, Kalali AH, et al. Efficacy and safety of lurasidone 80 mg\/day and 160 mg\/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial. Schizophr Res. 2013;145:101\u20139.","journal-title":"Schizophr Res"},{"key":"629_CR15","unstructured":"Chapel S, Chiu YY, Hsu J, Xu J, Cucchiaro, Loebel A. Dose\u2013response model of lurasidone treatment in schizophrenia. Poster presentation. American Psychiatric Association, May 5\u20139, 2012, Philadelphia, PA"},{"key":"629_CR16","unstructured":"US Food and Drug Administration: NDA Approval letter. [ http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2010\/200603s000ltr.pdf ]. Accessed October 12, 2015."},{"key":"629_CR17","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1007\/s00213-014-3765-1","volume":"232","author":"M Vermeiden","year":"2015","unstructured":"Vermeiden M, Kamperman AM, Vulink ME, van den Broek WW, Birkenh\u00e4ger TK. Early improvement as a predictor of eventual antidepressant treatment response in severely depressed inpatients. Psychopharmacology (Berl). 2015;232:1347\u201356.","journal-title":"Psychopharmacology (Berl)"},{"key":"629_CR18","doi-asserted-by":"crossref","first-page":"344","DOI":"10.4088\/JCP.07m03780","volume":"70","author":"A Szegedi","year":"2009","unstructured":"Szegedi A, Jansen WT, van Willigenburg AP, van der Meulen E, Stassen HH, Thase ME. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. J Clin Psychiatry. 2009;70:344\u201353.","journal-title":"J Clin Psychiatry"},{"key":"629_CR19","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.4088\/JCP.09m05874yel","volume":"72","author":"DE Kemp","year":"2011","unstructured":"Kemp DE, Johnson E, Wang WV, Tohen M, Calabrese JR. Clinical utility of early improvement to predict response or remission in acute mania: focus on olanzapine and risperidone. J Clin Psychiatry. 2011;72:1236\u201341.","journal-title":"J Clin Psychiatry"},{"key":"629_CR20","doi-asserted-by":"crossref","first-page":"155","DOI":"10.31887\/DCNS.2011.13.2\/ccorrell","volume":"13","author":"CU Correll","year":"2011","unstructured":"Correll CU, Kishimoto T, Kane JM. Randomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternatives. Dialogues Clin Neurosci. 2011;13:155\u201372.","journal-title":"Dialogues Clin Neurosci"},{"key":"629_CR21","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/JCP.0b013e31817e63a5","volume":"28","author":"BJ Kinon","year":"2008","unstructured":"Kinon BJ, Volavka J, Stauffer V, Edwards SE, Liu-Seifert H, Chen L, et al. Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study. J Clin Psychopharmacol. 2008;28:392\u2013400.","journal-title":"J Clin Psychopharmacol"},{"key":"629_CR22","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.eurpsy.2009.02.005","volume":"24","author":"M J\u00e4ger","year":"2009","unstructured":"J\u00e4ger M, Schmauss M, Laux G, Pfeiffer H, Naber D, Schmidt LG, et al. Early improvement as a predictor of remission and response in schizophrenia: Results from a naturalistic study. Eur Psychiatry. 2009;24:501\u20136.","journal-title":"Eur Psychiatry"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-015-0629-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T22:33:48Z","timestamp":1653431628000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.biomedcentral.com\/1471-244X\/15\/271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,31]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["629"],"URL":"https:\/\/doi.org\/10.1186\/s12888-015-0629-0","relation":{},"ISSN":["1471-244X"],"issn-type":[{"type":"electronic","value":"1471-244X"}],"subject":[],"published":{"date-parts":[[2015,10,31]]},"article-number":"271"}}